ReviewFrontiers in immunology2025
Harnessing the gut microbiome to modulate ferroptosis: a metabolic strategy for the treatment of digestive tract cancers.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The biphasic interactions between ferroptosis and oxidative stress: from molecular mechanisms to disease interventions.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis is a form of regulated cell death defined in recent years, characterized by iron-dependent accumulation of lipid peroxides. A large body of research has demonstrated that ferroptosis is closely associated with the progression of gastrointestinal tumors (such as gastric cancer, colorectal cancer, and esophageal cancer), and gastrointestinal tumor cells exhibit unique sensitivity to ferroptosis. This indicates that ferroptosis has emerged as a highly promising strategy to combat therapy-resistant colorectal cancer. Although the intrinsic ferroptosis-suppressive and ferroptosis-promoting pathways in gastrointestinal tumors have been fully elucidated, the current understanding of the extrinsic metabolites and pathways that regulate ferroptosis in the pathogenesis of gastrointestinal tumors remains relatively limited. Emerging studies have shown a strong link between gut microbial metabolism and the progression of gastrointestinal tumors. This review summarizes the relevant aspects of gut microbiota metabolism, explores how these gut microbiota-derived metabolites regulate cancer progression through ferroptosis, and proposes that targeting gut microbiota-mediated ferroptosis represents a potential therapeutic approach for gastrointestinal tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.